Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PPD
The agreement will accelerate the development of cell-based therapies, where Thermo Fisher will build and run a development center
The UK-headquartered life sciences investment firm has comfortably exceeded its target of $350m for a fund dedicated to taking on late-stage products, incurring all the clinical and regulatory risk and receiving a pre-negotiated return once the drug is approved.
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
- Contract Research Organization-CRO
- Contract Manufacturing Organization
- Other Names / Subsidiaries
- PPD Biotech, LLC